MAP2K7 and melanoma: As RAS-pathway mutations are frequent in CMML and the MEK-inhibitor trametinib is approved for melanoma and shows single-agent clinical activity in RAS mutated patients with myeloid malignancies including CMML [50], we tested the combination treatment of trametinib and azacitidine in vivo.